These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 26210956)

  • 1. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.
    Wu P; Nielsen TE; Clausen MH
    Drug Discov Today; 2016 Jan; 21(1):5-10. PubMed ID: 26210956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
    Roskoski R
    Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.
    Roskoski R
    Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Properties of FDA-approved small molecule protein kinase inhibitors.
    Roskoski R
    Pharmacol Res; 2019 Jun; 144():19-50. PubMed ID: 30877063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors.
    Du J; Yan H; Xu Z; Yang B; He Q; Wang X; Luo P
    Expert Opin Drug Metab Toxicol; 2021 Nov; 17(11):1311-1325. PubMed ID: 34743659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the translational value of pre-clinical studies for clinical response rate in oncology: an exploratory investigation of 42 FDA-approved small-molecule targeted anticancer drugs.
    Liu WA; Yu L; Morcos PN; Mercier F; Brennan BJ
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1015-1027. PubMed ID: 32424570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA-approved small molecule kinase inhibitors for cancer treatment (2001-2015): Medical indication, structural optimization, and binding mode Part I.
    Wang Y; Nan X; Duan Y; Wang Q; Liang Z; Yin H
    Bioorg Med Chem; 2024 Sep; 111():117870. PubMed ID: 39128361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early accelerated approval for highly targeted cancer drugs.
    Chabner BA
    N Engl J Med; 2011 Mar; 364(12):1087-9. PubMed ID: 21428763
    [No Abstract]   [Full Text] [Related]  

  • 9. Kinase Inhibitors FDA Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities.
    Latham BD; Geffert RM; Jackson KD
    Drug Metab Dispos; 2024 May; 52(6):479-492. PubMed ID: 38286637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA-approved small-molecule kinase inhibitors.
    Wu P; Nielsen TE; Clausen MH
    Trends Pharmacol Sci; 2015 Jul; 36(7):422-39. PubMed ID: 25975227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatotoxicity of FDA-approved small molecule kinase inhibitors.
    Jiang H; Jin Y; Yan H; Xu Z; Yang B; He Q; Luo P
    Expert Opin Drug Saf; 2021 Mar; 20(3):335-348. PubMed ID: 33356646
    [No Abstract]   [Full Text] [Related]  

  • 12. A cross-sectional study of the FDA approved indications and supporting pivotal trials of small-molecular kinase inhibitors in cancer therapies with the biomarker of cancer driver gene.
    Huang Y; Xiong W; Ma L; Wu H
    Int J Cancer; 2022 Dec; 151(12):2107-2114. PubMed ID: 35860988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules.
    Goebel GL; Qiu X; Wu P
    Trends Pharmacol Sci; 2022 Oct; 43(10):866-881. PubMed ID: 35589447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in kinase drug discovery: targets, indications and inhibitor design.
    Attwood MM; Fabbro D; Sokolov AV; Knapp S; Schiöth HB
    Nat Rev Drug Discov; 2021 Nov; 20(11):839-861. PubMed ID: 34354255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update.
    Roskoski R
    Pharmacol Res; 2022 Jan; 175():106037. PubMed ID: 34921994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.
    Zhong L; Li Y; Xiong L; Wang W; Wu M; Yuan T; Yang W; Tian C; Miao Z; Wang T; Yang S
    Signal Transduct Target Ther; 2021 May; 6(1):201. PubMed ID: 34054126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TransMolecular receives FDA approval for 131-I-TM-601 IND application.
    Expert Rev Anticancer Ther; 2002 Apr; 2(2):139. PubMed ID: 12113233
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated drug approval: FDA may get tougher; companies cite hurdles.
    Goozner M
    J Natl Cancer Inst; 2011 Mar; 103(6):455-7. PubMed ID: 21393609
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.
    Hojjat-Farsangi M
    J Drug Target; 2016; 24(3):192-211. PubMed ID: 26211367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.